JP2019525922A5 - - Google Patents

Download PDF

Info

Publication number
JP2019525922A5
JP2019525922A5 JP2019503470A JP2019503470A JP2019525922A5 JP 2019525922 A5 JP2019525922 A5 JP 2019525922A5 JP 2019503470 A JP2019503470 A JP 2019503470A JP 2019503470 A JP2019503470 A JP 2019503470A JP 2019525922 A5 JP2019525922 A5 JP 2019525922A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hydrogen
composition according
pharmaceutical
chlorine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019503470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019525922A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/044335 external-priority patent/WO2018022973A1/en
Publication of JP2019525922A publication Critical patent/JP2019525922A/ja
Publication of JP2019525922A5 publication Critical patent/JP2019525922A5/ja
Priority to JP2022006978A priority Critical patent/JP2022064923A/ja
Pending legal-status Critical Current

Links

JP2019503470A 2016-07-28 2017-07-28 癌を治療するための方法および組成物 Pending JP2019525922A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022006978A JP2022064923A (ja) 2016-07-28 2022-01-20 癌を治療するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367832P 2016-07-28 2016-07-28
US62/367,832 2016-07-28
PCT/US2017/044335 WO2018022973A1 (en) 2016-07-28 2017-07-28 Methods and compositions to treat cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022006978A Division JP2022064923A (ja) 2016-07-28 2022-01-20 癌を治療するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2019525922A JP2019525922A (ja) 2019-09-12
JP2019525922A5 true JP2019525922A5 (cg-RX-API-DMAC7.html) 2020-09-03

Family

ID=61017221

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019503470A Pending JP2019525922A (ja) 2016-07-28 2017-07-28 癌を治療するための方法および組成物
JP2022006978A Pending JP2022064923A (ja) 2016-07-28 2022-01-20 癌を治療するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022006978A Pending JP2022064923A (ja) 2016-07-28 2022-01-20 癌を治療するための方法および組成物

Country Status (5)

Country Link
US (4) US10668078B2 (cg-RX-API-DMAC7.html)
EP (1) EP3490555A4 (cg-RX-API-DMAC7.html)
JP (2) JP2019525922A (cg-RX-API-DMAC7.html)
AU (1) AU2017302617A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018022973A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525922A (ja) 2016-07-28 2019-09-12 チルドレンズ ホスピタル メディカル センター 癌を治療するための方法および組成物
EP4054585A1 (en) 2019-11-05 2022-09-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
TW202400160A (zh) * 2022-04-22 2024-01-01 美商米突倍基公司 轉錄因子eb活化子及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094009A2 (en) 2009-02-13 2010-08-19 Children's Hospital Medical Center Methods and compositions for the treatment of ras associated disorders
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
WO2013049585A1 (en) 2011-09-30 2013-04-04 Hengrui (Usa), Ltd. Arylsubstituted thiazolotriazoles and thiazoloimidazoles
US9664682B2 (en) * 2012-11-20 2017-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Assay to measure midkine or pleiotrophin level for diagnosing a growth
US9168257B2 (en) * 2013-05-22 2015-10-27 Children's Hospital Medical Center Combination therapy for MDS
EP3010504B1 (en) 2013-06-20 2018-10-31 Children's Hospital Medical Center Methods and compositions to treat cancer
JP2019525922A (ja) 2016-07-28 2019-09-12 チルドレンズ ホスピタル メディカル センター 癌を治療するための方法および組成物

Similar Documents

Publication Publication Date Title
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
JP2016518328A5 (cg-RX-API-DMAC7.html)
Schoenfeld Immunity in head and neck cancer
JOP20230035A1 (ar) مثبطات apol1 وطرق استخدامها
JP2017511377A5 (cg-RX-API-DMAC7.html)
JP2016518437A5 (cg-RX-API-DMAC7.html)
CN103402519B (zh) 肿瘤治疗剂
JP2020536888A5 (cg-RX-API-DMAC7.html)
JP2019524883A5 (cg-RX-API-DMAC7.html)
JP2015024998A5 (cg-RX-API-DMAC7.html)
JP2015508103A5 (cg-RX-API-DMAC7.html)
JP2018518537A5 (cg-RX-API-DMAC7.html)
JP2016518434A5 (cg-RX-API-DMAC7.html)
JP2016520618A5 (cg-RX-API-DMAC7.html)
JP2016512531A5 (cg-RX-API-DMAC7.html)
JP2018503663A5 (cg-RX-API-DMAC7.html)
JP2020506951A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
CN114072404A (zh) Ret选择性抑制剂及其制备方法和用途
JP2019516739A5 (cg-RX-API-DMAC7.html)
JP2019501879A5 (cg-RX-API-DMAC7.html)
JP2015521156A5 (cg-RX-API-DMAC7.html)
JP2019535723A5 (cg-RX-API-DMAC7.html)
GEAP202416543A (en) 4-phenyl-2-(1h-1,2,3-triazol-4-yl)piperidin-4-ol derivatives as inhibitors of apol1 and methods of using same